Last updated: September 9, 2026
The dasabuvir sodium, ombitasvir, paritaprevir and ritonavir combination was commercialized by AbbVie as Viekira Pak in the United States and as Viekirax plus Exviera in several other markets. It generated more than $1.6 billion in U.S. revenue in 2015, but sales declined rapidly as hepatitis C treatment shifted toward simpler, pan-genotypic regimens, especially Gilead Sciences’ Epclusa and AbbVie’s own Mavyret. The U.S. product was subsequently discontinued, leaving no meaningful forward revenue opportunity from the regimen.
What drug is the dasabuvir and ombitasvir/paritaprevir/ritonavir combination?
The regimen is a direct-acting antiviral treatment for chronic hepatitis C virus infection. Its components are:
| Component |
Pharmacologic role |
| Dasabuvir sodium |
Non-nucleoside NS5B polymerase inhibitor |
| Ombitasvir |
NS5A inhibitor |
| Paritaprevir |
NS3/4A protease inhibitor |
| Ritonavir |
Pharmacokinetic enhancer for paritaprevir |
In the U.S., the four-drug regimen was marketed as Viekira Pak. Viekira XR was a once-daily extended-release version. Ombitasvir, paritaprevir and ritonavir without dasabuvir were marketed as Technivie for genotype 4 infection.
Viekira Pak was approved by the U.S. Food and Drug Administration on December 19, 2014, for specified patients with genotype 1 chronic hepatitis C infection, with or without cirrhosis. Technivie was approved on July 24, 2015, for genotype 4 infection without cirrhosis (FDA, 2014, 2015).
How did Viekira Pak perform financially?
Viekira Pak had a steep launch followed by a sustained revenue collapse. AbbVie’s annual reports show the following approximate U.S. net revenue trajectory:
| Year |
Viekira Pak net revenue |
Year-over-year change |
| 2014 |
Approximately $100 million |
Launch year |
| 2015 |
Approximately $1.64 billion |
Rapid ramp-up |
| 2016 |
Approximately $1.0 billion |
Down about 39% |
| 2017 |
Approximately $480 million |
Down about 52% |
| 2018 |
Approximately $300 million |
Down about 37% |
| 2019 |
Less than $200 million |
Continued decline |
| 2020 onward |
Minimal or discontinued commercial contribution |
Product withdrawal |
The exact reported amount varies by AbbVie reporting period and whether revenues are presented by product, geography or product family. The core pattern is consistent: Viekira Pak became a major revenue contributor in 2015, then lost commercial relevance within roughly four years (AbbVie, 2015-2020).
The product’s launch economics were strong because HCV treatment had high clinical value and substantial untreated demand. The revenue decline reflected market substitution rather than a failure to achieve initial uptake.
Why did sales decline so quickly?
How did competing HCV drugs affect Viekira Pak?
Viekira Pak entered a highly competitive HCV market. Gilead’s Harvoni had been approved in October 2014, shortly before Viekira Pak. Harvoni offered a simpler once-daily tablet regimen and became the dominant genotype 1 treatment.
The competitive pressure intensified with:
- Gilead’s Epclusa, approved in 2016 as a pan-genotypic regimen;
- AbbVie’s Mavyret, approved in 2017 for all major HCV genotypes;
- Sovaldi-based combinations and other direct-acting antiviral regimens;
- aggressive payer negotiations and formulary exclusions.
Mavyret was strategically important because it was an AbbVie product capable of replacing Viekira Pak in much of the same treatment market. It offered pan-genotypic coverage, a shorter treatment duration for many patients and a lower list price than earlier HCV products. AbbVie began shifting commercial resources from Viekira Pak toward Mavyret soon after Mavyret’s launch.
Did treatment duration and convenience affect demand?
Yes. Viekira Pak required multiple tablets and, in many patients, ribavirin. Its regimen design was more complex than later once-daily or shorter-course products. HCV treatment rapidly moved toward:
- pan-genotypic coverage;
- eight- to 12-week treatment courses;
- fewer tablets;
- reduced need for ribavirin;
- simplified prescribing across patient populations.
Clinical cure rates remained high, but convenience, genotype breadth, payer access and price became decisive commercial variables.
What was the impact of pricing and payer negotiations?
The HCV market experienced rapid gross-to-net erosion. Public and private payers used preferred formulary placement, exclusive contracts and outcomes-oriented pricing to control treatment costs.
Viekira Pak’s launch followed the high-price model established by earlier curative HCV therapies. That model became difficult to sustain once multiple regimens offered comparable sustained virologic response rates. Payers could direct patients toward a preferred product, forcing manufacturers to provide substantial rebates.
Mavyret allowed AbbVie to compete on a lower list-price basis while protecting access across a broader genotype population. The shift reduced the strategic value of maintaining Viekira Pak as an independent franchise.
What FDA regulatory issues affected the product?
The FDA issued a safety communication in 2015 warning about serious liver injury associated with Viekira Pak and Technivie in some patients, particularly those with underlying advanced liver disease. The agency later required strengthened warnings regarding hepatic decompensation and liver failure risks.
The safety profile did not eliminate the regimen’s clinical utility, but it narrowed the addressable population and increased the attractiveness of alternative therapies with less complicated hepatic-use considerations. The FDA labeling also contained important restrictions and contraindications involving hepatic impairment and drug interactions (FDA, 2019).
Ritonavir created a substantial interaction burden because it affects cytochrome P450 metabolism. That issue increased prescribing complexity relative to later HCV regimens with fewer clinically significant interactions.
When did Viekira Pak lose market exclusivity?
Viekira Pak lost practical commercial exclusivity before patent expiry because the HCV market moved rapidly to newer products. Its effective commercial loss of exclusivity was driven by therapeutic substitution, payer contracting and product discontinuation rather than a conventional generic launch.
The primary commercial milestones were:
| Date |
Event |
| October 2014 |
Harvoni approved by FDA |
| December 19, 2014 |
Viekira Pak approved by FDA |
| July 24, 2015 |
Technivie approved by FDA |
| 2016 |
Epclusa approved by FDA |
| August 2017 |
Mavyret approved by FDA |
| 2019 |
HCV revenue becomes a minor AbbVie contributor |
| 2020 |
U.S. commercial availability of Viekira products ends or becomes negligible |
Exact patent expiry dates for individual active-ingredient, formulation and combination patents depend on the patent family, terminal disclaimers, patent-term adjustment and jurisdiction. Market exclusivity should therefore be distinguished from legal patent expiration.
What patents protected the Viekira Pak regimen?
Protection for the product was distributed across several patent categories rather than a single composition-of-matter right:
- Paritaprevir and related protease-inhibitor compounds.
- Ombitasvir and NS5A inhibitor compounds.
- Dasabuvir and polymerase-inhibitor compounds.
- Combination treatment regimens.
- Pharmaceutical compositions and dosage forms.
- Methods of treating genotype-specific HCV infections.
- Manufacturing processes and intermediates.
AbbVie and associated entities held the relevant intellectual-property rights. The commercial strength of the estate was highest during the first years after launch, when the active ingredients were protected by layered patents and the product had no clinically equivalent generic substitute.
The estate’s practical value declined as pan-genotypic competitors reduced demand. A patent estate can remain legally enforceable while having limited economic value if physicians and payers have already migrated to alternative therapies.
Were there Paragraph IV challenges to Viekira Pak?
The commercial record does not show a generic launch that materially displaced Viekira Pak in the United States. Any Paragraph IV activity would have been evaluated against a product with rapidly declining demand and a shrinking commercial opportunity.
For a generic applicant, the business case was weakened by:
- the regimen’s multi-component formulation;
- potential difficulty reproducing a combination pack;
- limited remaining demand;
- substitution by newer branded HCV products;
- physician preference for simpler pan-genotypic regimens;
- the absence of a large long-term maintenance market.
The relevant generic risk was therefore more likely to arise from patent settlement, authorized generic activity or niche-market entry than from a large-scale launch timed at the end of patent life.
What formulation and method-of-use rights mattered?
The product’s formulation and use protections were commercially relevant because Viekira Pak was sold as a coordinated combination package rather than as an ordinary single-ingredient tablet.
Potentially valuable claim areas included:
- fixed-dose or co-packaged administration;
- dosing schedules with or without ribavirin;
- genotype 1 treatment;
- treatment in patients with compensated cirrhosis;
- combinations with other antiviral agents;
- dosage regimens designed to improve paritaprevir exposure through ritonavir boosting.
Method-of-use claims were vulnerable to rapid obsolescence because HCV clinical practice changed quickly. Once pan-genotypic regimens became standard, genotype-specific method claims provided less commercial protection even if they remained legally valid.
How does Viekira Pak compare with Mavyret and Epclusa?
| Attribute |
Viekira Pak |
Mavyret |
Epclusa |
| Sponsor |
AbbVie |
AbbVie |
Gilead Sciences |
| Approval era |
2014 |
2017 |
2016 |
| Genotype coverage |
Primarily genotype 1 |
Pan-genotypic |
Pan-genotypic |
| Regimen complexity |
Relatively high |
Lower |
Lower |
| Treatment duration |
Commonly 12 weeks, depending on patient |
Often 8 weeks in eligible patients |
Commonly 12 weeks |
| Ribavirin use |
Required in some populations |
Less central to routine use |
Generally not required in standard use |
| Commercial position |
Discontinued or negligible |
AbbVie’s successor HCV franchise |
Major competing pan-genotypic product |
| Long-term revenue outlook |
Exhausted |
Mature but durable |
Mature but durable |
Mavyret represented the most direct internal replacement. Epclusa was the principal external benchmark for pan-genotypic coverage and simplified treatment.
Which companies challenged AbbVie’s market position?
The principal competitors were:
- Gilead Sciences, through Harvoni, Sovaldi and Epclusa;
- Merck, through Zepatier;
- Bristol Myers Squibb, through Daklinza;
- generic manufacturers and regional suppliers after relevant protections weakened;
- AbbVie itself, through Mavyret.
The competitive landscape was unusual because the principal threat to the older AbbVie regimen came both from external competitors and from AbbVie’s next-generation product.
What is the current commercial outlook?
The financial outlook for dasabuvir sodium with ombitasvir, paritaprevir and ritonavir is effectively exhausted in the United States. The regimen has no credible path to renewed high-volume growth because:
- newer direct-acting antivirals are clinically and operationally simpler;
- Mavyret and Epclusa cover broader patient populations;
- HCV treatment markets have moved toward curative, short-course therapy;
- the remaining untreated population is harder to reach;
- most commercial activity has shifted to diagnosis, access and public-health programs rather than premium branded launches;
- AbbVie has no strategic reason to rebuild the Viekira franchise while Mavyret remains available.
Residual revenue may persist in selected international markets, institutional channels or countries with delayed access to newer therapies. Those sales do not change the overall conclusion that the product is a legacy HCV asset.
What generic launch risks remain?
The remaining generic risk is commercially limited but not zero. Potential scenarios include:
- Regional generic entry after local patent expiry.
- Authorized supply arrangements in low-price markets.
- Generic substitution for individual components rather than the complete co-pack.
- Hospital or public-sector procurement of legacy regimens.
- Patent challenges that have little effect because demand is already small.
The greatest risk to any residual sales is not a conventional U.S. generic launch. It is continued clinical displacement and product withdrawal.
Key Takeaways
- Viekira Pak was the commercial product combining dasabuvir sodium, ombitasvir, paritaprevir and ritonavir.
- U.S. revenue peaked at approximately $1.6 billion in 2015.
- Sales declined rapidly because Harvoni, Epclusa and Mavyret offered simpler or broader treatment options.
- Mavyret was AbbVie’s direct successor and accelerated the decline of Viekira Pak.
- FDA liver-safety warnings and drug-interaction complexity weakened the product’s competitive position.
- The product’s patent estate had layered compound, formulation and method-of-use protection, but commercial value declined before patent expiry.
- No generic launch materially reshaped the U.S. market.
- The regimen has no meaningful forward growth trajectory and should be treated as a discontinued or legacy HCV asset.
FAQs
Is dasabuvir still commercially available in the United States?
No meaningful U.S. commercial market remains for Viekira Pak or Viekira XR. AbbVie shifted its HCV business to Mavyret.
What replaced Viekira Pak?
Mavyret replaced Viekira Pak within AbbVie’s portfolio. Epclusa and other pan-genotypic direct-acting antivirals replaced it across the broader HCV market.
Was Technivie the same as Viekira Pak?
No. Technivie contained ombitasvir, paritaprevir and ritonavir but did not contain dasabuvir. Viekira Pak contained all four components.
Does the regimen have biosimilar risk?
No. Biosimilars apply to biological products. These are small-molecule antiviral drugs, so the relevant threat is generic competition, not biosimilar substitution.
What is the investment view on the product?
The product has negligible growth value. Its historical revenue demonstrates successful launch execution, but its commercial lifecycle ended through therapeutic displacement, internal portfolio migration and market maturation.
References
-
AbbVie Inc. (2015-2020). Annual reports and Form 10-K filings. AbbVie.
-
U.S. Food and Drug Administration. (2014, December 19). FDA approves Viekira Pak to treat hepatitis C. https://www.fda.gov
-
U.S. Food and Drug Administration. (2015, July 24). FDA approves Technivie for treatment of hepatitis C genotype 4. https://www.fda.gov
-
U.S. Food and Drug Administration. (2019). FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. https://www.fda.gov
-
U.S. Food and Drug Administration. (2016). FDA approves new treatment for hepatitis C virus. https://www.fda.gov
-
U.S. Food and Drug Administration. (2017). FDA approves Mavyret for chronic hepatitis C. https://www.fda.gov
